HHS permits small pharmacies to compound six non-FDA-approved peptides
Just the facts

HHS permits small pharmacies to compound six non-FDA-approved peptides

Summary

The Department of Health and Human Services announced a policy allowing 503A compounding pharmacies to prepare six peptides that have not received FDA approval, sparking debate over safety and supply.

The U.S. Department of Health and Human Services issued a policy that grants enforcement discretion to small, 503A compounding pharmacies for six peptides that have not been approved by the Food and Drug Administration. The move is intended to provide a regulated alternative to the “research-use-only” products that are currently sold online.

Health Secretary Robert F. Kennedy Jr., a vocal supporter of peptide use, said he has personally used some of the substances. The peptides covered by the policy include BPC-157 (ulcerative colitis), Epitalon (insomnia), KPV (wound healing), MOTS-c (metabolic health), Semax (migraine) and TB-500 (wound healing).

The policy does not change the legal status of the peptides but creates a pathway for 503A pharmacies to compound them in limited quantities. Larger outsourcing facilities (503B) remain excluded.

"We won't be able to meet demand," said Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals, noting that his company will likely produce only one of the six peptides initially.

The Alliance for Pharmacy Compounding welcomed the decision, describing it as a more accountable option that brings patients under pharmacy standards, regulatory oversight and adverse-event reporting.

Consumer-advocacy groups expressed concern that the policy could expose patients to risks. Public Citizen criticized the approach, arguing that all peptide substances should undergo the standard FDA approval process. The Partnership for Safe Medicines filed a citizen petition urging the FDA to reject the advisory committee’s recommendation to allow compounding of the six peptides, warning that the decision leaves a “grey area” regarding safety.

Implementation may be delayed as ingredient suppliers verify that active ingredients meet the new requirements and pharmacies confirm compliance.

Source

NPR

Keep reading — for free

Create a free account to follow the news. No card required.